delta-9-tetrahydrocannabinol + cannabidiol + cannabichromene

This drug is a **combination of three naturally occurring cannabinoids found in cannabis plants**: delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabichromene (CBC). - **Delta-9-tetrahydrocannabinol** is the primary psychoactive constituent; it acts as a partial agonist of cannabinoid receptors (CB1 and CB2), producing analgesic, antiemetic, appetite-stimulating, muscle relaxant, anxiolytic, and neuroprotective effects[1][3][5]. - **Cannabidiol** is a non-intoxicating cannabinoid that acts as a negative allosteric modulator of CB1/CB2 and interacts with multiple other targets (e.g., TRPV1, 5-HT1A, GPR55), providing anticonvulsant, anxiolytic, anti-inflammatory, and neuroprotective actions[3]. - **Cannabichromene** is a minor cannabinoid thought to contribute anti-inflammatory, analgesic, and potential neuroprotective effects, via interactions with TRPA1, TRPV1, and other non-cannabinoid targets. This specific combination may be used to optimize therapeutic effects and reduce certain adverse effects of THC alone (such as anxiety, cognitive impairment). It is primarily indicated for analgesia in chronic pain (including neuropathic pain and fibromyalgia), epilepsy, neurodegenerative diseases, cancer-related symptoms (nausea, vomiting, cachexia), mood disorders, and other disorders where cannabinoids are potentially beneficial[1][3][5].